HighTower Advisors
ENZN

HighTower Advisors’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

HighTower Advisors’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-17,883
Closed -$18K – 1766
2014
Q1 		$18K Buy
+17,883
New +$18.5K ﹤0.01% 1495

Other funds holding ENZN

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HighTower Advisors's ENZN Position: Q2 2014 in Review

HighTower Advisors sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q2 2014, closing a stake of 17,883 shares — an estimated $18K sold.

HighTower Advisors first reported a position in ENZN in Q1 2014 and held it in 1 quarter. The position peaked at $18K in Q1 2014. 67 funds tracked by Wall St. Rank hold ENZN as of Q2 2014.

  • HighTower Advisors reported no remaining ENZON PHARMACEUTICALS INC position as of Q2 2014 after selling out during the quarter.
  • HighTower Advisors sold 17,883 ENZON PHARMACEUTICALS INC shares in Q2 2014, an estimated $18K.
  • HighTower Advisors first reported a position in ENZON PHARMACEUTICALS INC in Q1 2014 and held it in 1 quarter.
  • HighTower Advisors's ENZON PHARMACEUTICALS INC position peaked at $18K in Q1 2014.
  • 67 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q2 2014.

Based on HighTower Advisors's 13F filing for Q2 2014, filed 13 Aug 2014.